C2i Genomics is a company.
C2i Genomics has raised $112.0M across 2 funding rounds.
Key people at C2i Genomics.
C2i Genomics was founded by Asaf Zsviran (Co-Founder, CEO & CSO).
C2i Genomics has raised $112.0M in total across 2 funding rounds.
C2i Genomics is a biotechnology company that develops a cutting-edge cancer monitoring platform using whole-genome sequencing combined with artificial intelligence (AI). Its flagship product, the C2inform minimal residual disease (MRD) test, enables ultra-sensitive detection and real-time monitoring of cancer recurrence and progression from a small blood sample. This technology serves oncologists, pharmaceutical companies, and patients by providing earlier and more accurate insights into cancer treatment response and disease status, potentially improving outcomes and guiding personalized therapies. The company has demonstrated strong growth momentum through regulatory certifications, global collaborations, and commercial partnerships, culminating in its acquisition by Veracyte in early 2024[1][2][3].
Founded in 2019 by Ezra Sofer and others with expertise in genomics and AI, C2i Genomics emerged from the need to improve cancer monitoring beyond traditional imaging and biopsy methods. The idea was to leverage whole-genome sequencing data and machine learning to detect subtle tumor DNA changes in blood, enabling earlier detection of recurrence. Early traction included raising $12 million in Series A funding led by Casdin Capital and NFX Capital in 2020, which supported clinical validation and platform development. The company’s rapid technological advances and partnerships have positioned it as a pioneer in liquid biopsy diagnostics[1][3].
C2i Genomics rides the wave of precision oncology and liquid biopsy innovation, addressing the critical need for non-invasive, highly sensitive cancer monitoring tools. The timing is crucial as cancer care increasingly shifts toward personalized treatment guided by genomic data. Market forces such as rising cancer incidence, demand for real-time treatment monitoring, and advances in AI and sequencing technologies favor C2i’s approach. By democratizing access to whole-genome cancer monitoring and integrating AI-driven insights, C2i influences the broader ecosystem by enabling earlier interventions, reducing healthcare costs, and accelerating drug development[1][3][4].
Looking ahead, C2i Genomics aims to expand its AI platform beyond MRD testing to extract richer diagnostic insights from whole-genome sequencing, potentially creating a suite of tools for precise cancer diagnosis and treatment guidance. Integration into Veracyte’s portfolio will likely accelerate commercialization and global reach. Trends such as increasing adoption of AI in healthcare, growing demand for liquid biopsies, and advances in genomic data analytics will shape C2i’s trajectory. Its influence is expected to grow as it helps transform cancer care from reactive to proactive management, improving patient outcomes worldwide[1][2].
In summary, C2i Genomics stands out as a pioneering company at the intersection of genomics and AI, delivering transformative cancer monitoring solutions that promise to reshape oncology diagnostics and treatment.
C2i Genomics was founded by Asaf Zsviran (Co-Founder, CEO & CSO).
C2i Genomics has raised $112.0M in total across 2 funding rounds.
C2i Genomics's investors include Album VC, NFX, Casdin Capital.
Key people at C2i Genomics.
C2i Genomics has raised $112.0M across 2 funding rounds. Most recently, it raised $100.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $100.0M Series B | Album VC, NFX | |
| Jun 1, 2020 | $12.0M Series A | Album VC, Casdin Capital, NFX |
